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the role of CXCR3 in non-alcoholic steatohepatitis (NASH)
remains unclear. We aimed to investigate the role of CXCR3 in
NASH.
Methods: Human liver tissues were obtained from 24
non-alcoholic fatty liver disease (NAFLD) patients and 20 control
subjects. CXCR3 knockout (CXCR3/), obese db/db mice and
their wild-type (WT) littermates were used in both
methionine-and-choline-deficient (MCD) diet and high-fat
high-carbohydrate high-cholesterol (HFHC) diet-induced NASH
models. In addition, MCD-fed WT mice were administrated with
CXCR3 specific antagonists.
Results: CXCR3 was significantly upregulated in liver tissues of
patients with NAFLD and in dietary-induced NASH animal mod-
els. Compared with WT littermates, CXCR3/ mice were more
resistant to both MCD and HFHC diet-induced steatohepatitis.
Induction of CXCR3 in dietary-induced steatohepatitis was
associated with the increased expression of hepatic
pro-inflammatory cytokines, activation of NF-jB, macrophage
infiltration and T lymphocytes accumulation (Th1 and Th17Journal of Hepatology 20
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reticulum (ER) stress in steatohepatitis as evidenced by LC3-II
and p62/SQSTM1 accumulation and the induction of GRP78,
phospho-PERK and phospho-eIF2a. Inhibition of CXCR3 using
CXCR3 antagonist significantly suppressed MCD-induced steato-
sis and hepatocytes injury in AML-12 hepatocytes. Blockade of
CXCR3 using CXCR3 antagonists in mice reversed the established
steatohepatitis.
Conclusions: CXCR3 plays a pivotal role in NASH development by
inducing production of cytokines, macrophage infiltration, fatty
acid synthesis and causing autophagy deficiency and ER stress.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Chemokines and their receptors which regulate the infiltration of
immune cells to sites of inflammatory injury play a crucial role in
both acute and chronic inflammation [1]. Non-alcoholic fatty
liver disease (NAFLD), and its pathologically more severe form
non-alcoholic steatohepatitis (NASH), has a worldwide distribu-
tion paralleled with the rapidly increasing incidence of metabolic
syndrome [2]. Chemokines and their corresponding receptors
have been identified to be the lynchpin in the transition of simple
steatosis to steatohepatitis [2,3]. However, the molecular mecha-
nism behind the chemokine receptors-mediated steatohepatitis
is still largely unknown. Chemokine receptor antagonists have
already been applied in clinical trials for intervention in inflam-
matory diseases and cancer [4]. Therefore, elucidation of the
effect of chemokine receptor on the development of steatohepati-
tis may enable the development of novel pharmacological treat-
ments for this disorder.
CXCR3, a G protein-coupled receptor for cytokines CXCL10
(IP-10), CXCL11 (I-TAC) and CXCL9 (MIG), is essential in chronic
liver inflammation and HCV infection [5,6]. CXCR3 is highly16 vol. 64 j 160–170
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expressed in T cells, monocytes/macrophages and resident cells
[7]. It contributes to macrophage activation in mice [8,9]. CXCR3
has been recently identified to play a role in diet-induced obesity
and insulin resistance [10], suggesting its role in the development
of intrahepatic inflammation and metabolic syndrome. Yet, the
potential effect of CXCR3 and the mechanism of its action in
steatohepatitis are still unknown. Importantly, no evidence is
available on whether CXCR3 can be targeted for the treatment
of steatohepatitis. In this study, we evaluated the significance
of CXCR3 in experimental nutritional steatohepatitis and the
potential therapeutic effect of CXCR3 antagonists for the treat-
ment of steatohepatitis.Table 1. Clinical characteristics of all patients’ population.
Normal NAFLD
All 20 24
Male gender 11 (55) 9 (37.5)
Age (years) 45.1 (16.9) 41.0 (9.5)
Body weight (kg)** 56.5 (10.2) 108.7 (18.8)
BMI** 22.5 (3.0) 38.8 (4.6)
Metabolic syndrome** 1 (5.0) 17 (70.8)
ALT (IU/L) 52.0 (61.8) 88.6 (62.1)
Fasting glucose (mmol/L)* 5.1 (1.0) 7.3(3.0)
NAFLD score 0 3.1 (1.5)
Liver TG content (%) 3.5 (6.6)
Steatosis grade 1/2/3 9/7/8
Lobular inflammation 0/1 12/12
Ballooning 0/1/2 11/11/2
Fibrosis 0/1/2/3 13/7/1/3
*Significant at p <0.05; **significant at p <0.0001, between normal subjects and
NAFLD patients. Numbers in parentheses are percentage for categorical data or
standard deviation for numerical data.
ALT, alanine aminotransferase; BMI, body mass index; TG, triglyceride.Materials and methods
Human samples
Human liver tissue samples were collected under percutaneous liver biopsy from
24 NAFLD patients from Price of Wales Hospital, the Chinese University of Hong
Kong. Twenty normal liver tissues were obtained from the donors of liver trans-
plantation in Queen Mary Hospital, the University of Hong Kong. Liver biopsy
specimens were fixed and embedded. Histological slides were accessed and
scored by two pathologists. NAFLD patients were diagnosed as steatosis with or
without lobular inflammation and ballooning [11]. Control subjects had normal
liver histology without the history of diabetes or hypertention [12]. All subjects
were given written informed consent prior to sample collection and the study
protocol was approved by the Clinical Research Ethics Committee of the Chinese
University of Hong Kong and the Ethics Committee of the University of Hong
Kong.
Animals and treatments
CXCR3/ mice (C57BL/6 strain) were generated by targeted deletion of a 2.5 kb
HINDIII and XbalI fragment and replaced by PGK-neo [13]. Age-matched male
CXCR3/, C57BL/6 wide-type (WT) littermates were fed randomly either with
methionine-and-choline-deficient (MCD) (ICN Biomedical, Costa Mesa, CA) or
control diet for 4 weeks to induce steatohepatitis and for 8 weeks to induce
fibrosing steatohepatitis [12,14]. Age-matched leptin receptor deficient db/db
mice (genetic obesity and insulin resistance) were fed with MCD or control diet
for 10 days.
In a separate experiment, CXCR3/ andWTmice were fed with high-fat high-
carbohydrate high-cholesterol (HFHC) diet (Specialty feeds, Glen forrest, WA,
Australia) and drinking water supplement with high fructose. The HFHC diet
(181 g/kg lard, 50 g/kg canola oil, 424 g/kg sucrose, 200 g/kg acid casein,
50 g/kg cellulose and 2.03 g/kg cholesterol) provides 23% kcal from fat, 47.4% kcal
from carbohydrates and 19.4% kcal from proteins. 23 g/L fructose (Sigma, St.
Louis, MO) was provided in drinking water [15]. Animals were provided ad libitum
access to these diets for 12 weeks.
C57BL/6 WT mice were given AMG487 subcutaneously (5 mg/kg, daily) (R&D
systems, Minneapolis, MN), an antagonist of CXCR3, for 10 consecutive days start
at 2 weeks following MCD diet [16]. AMG487 was diluted in 20% of hydroxypropyl-
b-cyclodextrin (Sigma) solution. Mice were also given 20% hydroxypropyl-b-
cyclodextrin as controls. In addition, another CXCR3 antagonist SCH546738
(Medchemexpress LLC, Princeton, NJ), which was prepared in 0.4% methylellulose
(Sigma), was also applied in C57BL/6 WT mice at 10 mg/kg daily for 10 days [17]
at 2 weeks following MCD diet.
All animal studies were performed in accordance with guidelines approved
by the Animal Experimentation Ethics Committee of the Chinese University of
Hong Kong.
Adoptive transfer
Mice macrophages were obtained from the peritoneal cavities of MCD-fed
C57BL/6 WT mice four days after intraperitoneal injection of 3% Brewer thiogly-
collate medium (BD Biosciences, Franklin Lakes, NJ). Briefly, mouse peritoneal
cavity was lavaged with 10 ml ice-cold DMEM medium. The peritoneal fluid
was dispensed and the cell concentration was adjusted to 3  106 nucleated
cells/ml in DMEM/F12 medium supplemented with 10% FBS. The macrophagesJournal of Hepatology 201were cultured in a humidified incubator at 37 C for 2 h. Non-adherent cells were
removed by gentle washing three times with warm PBS. The purity of cell suspen-
sion was analyzed by flow cytometry and more than 97% of adherent cells were
macrophages. 4.5  106 cells/mouse were injected intraperitoneally into MCD-
fed CXCR3/ mice 48 h before harvest [18].
Mice T cells were isolated from the spleen of MCD-fed C57BL/6 WT mice with
a MACS pan T cell isolation kit (Miltenyi Biotec, Auburn, CA). The purity of the cell
separation was about 99% as assessed by flow cytometry. After isolation, 1  107
cells were adoptively transferred to each recipient CXCR3/ mouse by tail vein
injection. The effects of adoptive transfer on T cell populations and phenotypes
were evaluated 48 h after the adoptive transfer by fluorescence-activated cell
sorting (FACS) analysis.
Additional experimental procedures are provided in the Supplementary
material.Results
CXCR3 is upregulated in human NAFLD and murine steatohepatitis
We first evaluated the expression of CXCR3 in human liver tis-
sues of 24 NAFLD subjects and 20 normal controls. The clinical-
pathological characteristics of these subjects were shown in
Table 1. As determined by real-time PCR, CXCR3 mRNA expres-
sion was significantly higher in human NAFLD compared with
normal controls (2.70 ± 1.77 vs. 1.42 ± 1.14, p = 0.0078)
(Fig. 1A). The upregulated CXCR3 protein level in human NAFLD
tissues was confirmed by immunohistochemistry (Fig. 1B). The
CXCR3 protein levels were found to be associated with CXCR3
mRNA levels in human samples from NAFLD subjects (r = 0.464,
p <0.05, Fig. 1B). Immunohistochemistry analysis of CXCR3 also
showed that human CXCR3 was mainly expressed in inflamma-
tory cells and hepatocytes near portal area (Fig. 1B). We further
confirmed the increased CXCR3 expression in both dietary and
genetic db/db models of murine steatohepatitis. CXCR3 mRNA
expression was 2.5-fold higher in steatohepatitis in WT fed
MCD compared to the control diet fed WT mice for 4 weeks
(p <0.05, Fig. 1C). Similar to human data, immunohistochemistry
analysis confirmed an increased CXCR3 protein expression in6 vol. 64 j 160–170 161
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Fig. 1. CXCR3 is upregulated in liver tissues of human NAFLD and murine steatohepatitis. (A) CXCR3 mRNA expression was significantly increased in human NAFLD
tissues compared to normal liver tissues by quantitative real time PCR (qRT-PCR); (B) Representative immunohistochemistry images of CXCR3 protein expression in human
normal liver tissues and NAFLD tissues. (C) Hepatic CXCR3 mRNA expression (qRT-PCR) in liver tissues of WT and CXCR3/ mice, fed with control or MCD; (D)
Representative immunohistochemistry images of CXCR3 protein expression in WT mice fed with control or MCD diet; (E) Representative H&E staining from db/db mice fed
with control or MCD diet; (F) Hepatic CXCR3 mRNA expression (qRT-PCR) in db/db mice fed control or MCD diet. Values are mean ± SD.
Research Articlemouse steatohepatitis. CXCR3 was mainly expressed in inflam-
matory cells and hepatocytes near portal area (Fig. 1D). Obese
db/dbmice fed with MCD diet for 10 days developed early steato-
hepatitis with fatty droplet accumulation and inflammatory cell
infiltration (Fig. 1E). CXCR3 mRNA expression was 4.0-fold higher
in db/db mice fed with MCD diet compared with control diet fed
mice (p <0.05) (Fig. 1F).
Upregulated CXCR3 is implicated in the pathogenesis of
steatohepatitis in mice induced by the MCD diet
Mice fed with a control diet displayed normal histology (Fig. 2A).
Upon feeding the MCD diet for 4 weeks, WT mice developed
steatohepatitis with hepatocyte ballooning changes and inflam-
matory cell infiltration (Fig. 2A); conversely, CXCR3/ mice had
significantly lower scores of hepatic steatosis (0.5 0 ± 0.35 vs.
2.20 ± 0.27; p <0.0001) and necroinflammation (0.70 ± 0.27 vs.
2.20 ± 0.27; p <0.0001) compared to WT mice fed with MCD.
Keeping with the diminished hepatic inflammation in CXCR3/
mice, serum ALT level was significantly lowered in CXCR3/mice
compared to WT mice fed MCD (p <0.0001) (Fig. 2B). Similarly,
hepatic lipid peroxide (p <0.05) (Fig. 2C) and triglyceride
(Fig. 2D) contents (p <0.0001) were significantly reduced in
CXCR3/ mice fed MCD. However, the hepatic mRNA levels of
other CXC chemokine receptors and their ligands including CXCR4
and its ligand CXCL12, CXCR6 and its ligand CXCL16 did not
show significant differences between MCD-fed CXCR3/ mice
and WT mice (Supplementary Fig. 1). These results therefore162 Journal of Hepatology 201indicated that CXCR3 deletion weakened the development of
steatohepatitis.
CXCR3 induces hepatic chemokine expression and activates NF-jB
To characterize the mechanism of CXCR3-induced inflammation,
levels of hepatic cytokine/chemokine production of WT and
CXCR3/ mice were examined using cytokine profiling assay.
As shown in Fig. 3A, CXCR3 deficiency significantly reduced the
levels of pro-inflammatory cytokines including tumor necrosis
factor alpha (TNF-a), monocyte chemoattractant protein-1
(MCP-1) and interleukin (IL)-5 compared to WT mice.
As cytokines TNF-a and MCP-1 contribute to the activation of
NF-jB in steatohepatitis [19], we examined the effect of CXCR3
on NF-jB activation. We found that NF-jB p65 nuclear DNA-
binding activity, protein expression of phosphorylated NF-jB
subunits p50 and mRNA expression of NF-jB downstream factor
intercellular adhesion molecule-1 (ICAM-1) were markedly
blunted in CXCR3/ mice compared to WT mice fed MCD
(Fig. 3B). To address whether the impairment of NF-jB was
dependent on TNF-a, MCD medium cultured mouse hepatocyte
AML-12 was subjected to anti-TNFR1 mAb with or without
CXCR3 antagonist (NIBR2130). Protein expression of phosphory-
lated NF-jB p105 and phosphorylated NF-jB p50 was decreased
in AML-12 cells after the blockade of TNF-a by anti-TNFR1 mAb
in the presence of CXCR3 antagonist (Supplementary Fig. 2), sug-
gesting that the impairment of NF-jB by CXCR3 deficiency was
partially dependent on TNF-a.6 vol. 64 j 160–170
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Fig. 2. Deletion of CXCR3 protects against MCD diet-induced steatohepatitis.
(A) Representative H&E staining (arrows, inflammatory cells) from 4-week liver
sections of C57BL/6 WT (upper panel) and CXCR3/ (lower panel) mice fed
control (left panel) or MCD diet (right panel) were shown. (B) Serum ALT; (C)
Total hepatic lipoperoxide and (D) liver triglyceride content in WT and CXCR3/
mice fed control or MCD diet. Values are mean ± SD (n = 5/group). *p <0.05,
**p <0.001 vs. same genotype mice fed control diet.
JOURNAL OF HEPATOLOGYCXCR3 promotes macrophage infiltration
It is known that TNF-a and MCP-1 are mainly produced by acti-
vated macrophages [20], we investigated whether CXCR3 could
regulate hepatic macrophage infiltration. The results showed that
macrophage infiltration as determined by F4/80 immunostaining
was increased in WT mice, but not in CXCR3/ mice fed MCD
(p <0.001) (Fig. 3C). The impaired macrophage infiltration in
CXCR3/ mice was confirmed by the decrease mRNA expression
of F4/80,MCP-1 and CCR2 in CXCR3/mice compared to WT mice
(Fig. 3D and E). It is known that macrophage proliferation is pos-
itively correlated with MCP-1 expression [21]. We found that
CXCR3 mRNA level was positively associated with MCP-1 mRNA
level (r = 0.5728, p <0.01) in human NAFLD tissues (Fig. 3F). These
results collectively suggest that CXCR3 promotes hepatic macro-
phage infiltration.
To further dissect the role of CXCR3 in regulating the infiltra-
tion of macrophages in steatohepatitis, macrophages purified
from peritoneal cavities of MCD-fed WT mice were adoptively
transferred into MCD-fed CXCR3/ mice. Adoptive transferring
WT macrophages to CXCR3/ mice led to a significant increaseJournal of Hepatology 201of protein expression of phosphorylated NF-jB p65, phosphory-
lated NF-jB p50 and pro-inflammatory cytokine TNF-a than
the mice without macrophage transfer (Supplementary Fig. 3).
These data indicated that the detrimental effect of CXCR3 in
steatohepatitis is at least dependent on hepatic macrophage
infiltration.
CXCR3 mediates Th1 and Th17 immune response in liver tissues
CXCR3 is a key chemokine receptor of T cells. To investigate the
role of T cells in CXCR3-induced liver steatohepatitis, we evalu-
ated the quantity and phenotype of the T cells in WT and
CXCR3/ mice by FACS analysis. As shown in Fig. 4A, MCD-
fed CXCR3/ mice contained fewer CD3+ T lymphocytes in their
liver tissues compared to WT mice fed with MCD diet (p <0.01).
As CXCR3 has been indicated in Th1 and Th17 immune response
[22,23], we further performed intracellular staining of hepatic
IFN-c positive T cells and IL-17 positive T cells in WT and
CXCR3/ mice. The recruitment of Th1 cells (CD4+IFN-c+ T cells)
and Th17 cells (CD4+IL-17+ T cells) into the liver after MCD chal-
lenge was reduced in CXCR3/ mice compared with their WT
littermates (Fig. 4B–C). CD3+ total T cells and IL-17 producing
Th17 cells, but not IFN-c producing Th1 cells, could be restored
by adoptive transfer of WT T cells (Fig. 4). These results sug-
gested that CXCR3 deficiency ameliorated steatohepatitis
through the attenuation of both the Th1 and Th17 immune
response.
CXCR3 induces hepatic expression of lipogenic genes
To define the molecular basis of less steatosis observed in
CXCR3/ mice, we assessed hepatic expression of lipogenic and
lipolytic genes. Compared to MCD-fed WT mice, MCD-fed
CXCR3/ mice showed significantly reduced mRNA expression
of key lipogenic genes including liver X receptors (LXRa, LXRb),
sterol regulatory element binding protein isoform-1c (SREBP-
1c), fatty acid synthase (FAS) and stearoly-CoA desaturase
isoform-1 (SCD-1) (Fig. 5A) Concomitantly, the nuclear DNA-
binding activity of SREBP-1c was decreased in CXCR3/ mice
(Fig. 5B). There were no significant differences in hepatic mRNA
levels of fatty acid oxidation genes between CXCR3/ mice and
WT mice (Fig. 5C). Moreover, CXCR3 mRNA expression was posi-
tively associated with SREBP-1 mRNA expression (r = 0.4883,
p <0.01) in human NAFLD tissues (Fig. 5D). These results sug-
gested CXCR3 induces lipogenesis by upregulating lipogenic
regulators.
CXCR3 induces hepatic autophagy
Autophagy is known to play a critical role in inflammatory condi-
tions. CXCR3 regulates autophagy in inflammatory diseases and
cancer [24,25]. We thus investigated the effect of CXCR3 on hep-
atic autophagy in experimental steatohepatitis. We found that
protein expression of key autophagy related proteins p62 and
LC3-II were increased in MCD-fed WT mice with severe steato-
hepatitis compared to MCD-fed CXCR3/ mice with blunted
steatohepatitis (Fig. 6A). Concomitantly, p62-positive aggregate
was significantly less in CXCR3/ mice than in WT mice fed
MCD (Fig. 6B). As the accumulation of both p62 and LC3-II indi-
cates autophagic flux inhibition [26] and the deposit of p62 in
the liver is caused by liver-specific autophagy defects [27], our6 vol. 64 j 160–170 163
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Fig. 3. Hepatic chemokines expression, NF-jB activity and macrophage recruitment were decreased in liver tissues of CXCR3/ mice. (A) Hepatic TNF-a, MCP-1 and
IL-5 protein levels in the livers fromWT and CXCR3/mice fed with control or MCD diet for 4 weeks were quantified by cytokine profiling assay. (B) NF-jB nuclear binding
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Research Articleresults suggest that autophagy was impaired in experimental
steatohepatitis and ablation of CXCR3 could restore autophagy
in this disorder. The increased p62 levels could be caused either
by increased accumulation or by impaired consumption in lyso-
some. To address this issue, we analyzed the expression of two
markers of lysosomal storage disorder, lysosome-associated
membrane protein 1 (LAMP1) and LAMP2 [28]. The protein levels
of LAMP1 and LAMP2 were markedly lower in CXCR3/ mice
compared to WT mice fed MCD fed (Fig. 6C), suggesting impaired
consumption in lysosome was involved in CXCR3-associated
steatohepatitis. Collectively, these results indicated that CXCR3
disrupted lysosome function, aggregated p62, thereby impaired
autophagy in steatohepatitis.
CXCR3 induces hepatic UPS and ER stress in mice
Inhibition of ubiquitin-proteasome system (UPS) can induce
autophagy, whilst, p62 accumulation caused by autophagy
inhibition impairs the delivery of polyubiquitinated proteins
[29]. We found that the polyubiquitinated proteins were
induced in WT mice compared with MCD-fed CXCR3/ mice
fed MCD (Fig. 6D), inferring CXCR3 induces ubiquitin-
proteasome aggregation. It is known that accumulation of
polyubiquitinated proteins can induce endoplasmic reticulum
(ER) stress [30], which results in p62-positive polyubiquitinated
proteins aggregation [31]. We thus examined the expression of
ER stress markers in the liver tissues of WT and CXCR3/164 Journal of Hepatology 201mice. The protein levels of ER stress markers, including
GRP78, PDI, p-PERK, p-eIF2a and eIF2a were increased in WT
mice fed with MCD diet compared with those fed with control
diet. In keeping with the decreased polyubiquitinated proteins,
MCD-fed CXCR3/ mice showed significantly reduced protein
levels of GRP78, PDI, p-PERK, p-eIF2a and eIF2a compared to
MCD-fed WT mice (Fig. 6E). Apoptosis as indicated by TUNEL
staining was also induced in WT mice compared with CXCR3/
mice fed MCD (Fig. 6F). Collectively, our results suggest that
CXCR3 suppresses autophagy, thereby activating UPS and ER
stress, contributing to the development of steatohepatitis.
CXCR3 is implicated in the pathogenesis of steatohepatitis in mice
induced by the HFHC diet
To confirm the effects of CXCR3 in MCD-induced steatohepatitis
model, an additional experiment was performed on HFHC-
induced mice steatohepatitis. In this HFHC-induced NASH model,
CXCR3/ mice showed much improved liver histology (Fig. 7A)
as indicated by significantly lower score of necroinflammation
(WT mice vs. CXCR3/ mice; 0.92 ± 0.33 vs. 0.20 ± 0.12;
p <0.01) and reduced lipid peroxidation (WT mice vs. CXCR3/
mice; 2.91 ± 0.67 vs. 2.43 ± 0.47; p <0.05). Phosphorylated NF-
jB subunits of p105 and p65 was decreased in CXCR3/ mice
compared to WT mice fed HFHC diet (Fig. 7A). Thus, CXCR3
induces steatohepatitis in high-fat diet induced mice steatohep-
atitis model.6 vol. 64 j 160–170
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JOURNAL OF HEPATOLOGYInhibition of CXCR3 by a specific CXCR3 antagonist suppresses
steatosis and hepatocyte injury in AML-12 cells
We next evaluated the effect of inhibition of CXCR3 by a specific
CXCR3 antagonist (NIBR2130) on AML-12 hepatocytes. When
AML-12 cells exposed to the MCD medium for 24 h, there was a
significant increase in hepatic triglyceride and lipid peroxide
levels compared with the control medium (Supplementary
Fig. 4A). However, when AML-12 cells were incubated in MCD
medium in the presence of NIBR2130 (0.1 lM, 1 lM or 10 lM),
there was a dose-dependent decrease of triglyceride and lipid
peroxide contents (Supplementary Fig. 4A). Keeping with these,
NIBR2130 treatment significantly lowered the mRNA expression
of TNF-a (Supplementary Fig. 4A) and protein expression of
p62, LAMP1 and LAMP2 (Supplementary Fig. 4B) in AML-12
hepatocytes cultured in MCD medium for 24 h.
Inhibition of CXCR3 by its antagonists reverses steatohepatitis in
mice
We next examined whether treatment of CXCR3 antagonists
could reverse the established steatohepatitis in mice. Two CXCR3
antagonists, AMG487 and SCH546738, were administrated to
C57BL/6 mice after 2 weeks MCD feeding. We found that CXCR3Journal of Hepatology 201protein expression was decreased after treatment with
SCH546738 or AMG487 for 10 days (Supplementary Fig. 5A).
Administration of SCH546738 and AMG487 to MCD-diet fed
WT mice significantly improved the liver histology as evaluated
by reduced scores of steatosis and inflammatory cell infiltration
(Supplementary Fig. 5B), with a concordant reduction of
hepatic triglyceride and lipid peroxide (Supplementary Fig. 5C).
Likewise, CXCR3 inhibition by SCH546738 and AMG487 sup-
pressed macrophage recruitment as evidenced by reduced
F4/80 positive macrophage infiltration and F4/80 mRNA
expression (Supplementary Fig. 5D). Moreover, blocking CXCR3
restored autophagy and lysosome function as evidenced by
decreased protein expression of p62, LC3 and LAMP2
(Supplementary Fig. 5E).
CXCR3 prevents MCD-induced liver fibrosis in mice
To examine whether CXCR3 plays a role in hepatic nutritional
fibrosis, CXCR3/ mice and WT mice were fed with control or
MCD diet for 8 weeks. Despite much improved inflammation in
steatohepatitis, MCD-fed CXCR3/ mice displayed exaggerated
liver fibrosis, which is consistent with data published by others
[5,32]. Lack of CXCR3 resulted in enhanced amount of collagen
fibers by Sirius Red staining, higher hepatic hydroxyproline6 vol. 64 j 160–170 165
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Research Articlecontent and increased hepatic stellate cells activation as
indicated by increased alpha-smooth muscle actin (a-SMA)
protein and mRNA expression (Supplementary Fig. 6).Fig. 6. Autophagy is induced in the absence of CXCR3. (A) Hepatic protein
expression of LC3 and p62 by Western blot. GAPDH served as loading control; and
(B) Representative images of p62 protein expression and localization by
immunohistochemistry in liver tissues from WT and CXCR3/ mice fed control
or MCD diet; (C) Hepatic protein expression of LAMP-1, LAMP-2; (D) polyubiq-
uitinated proteins expression and (E) ER stress markers GRP78, PDI, p-PERK,
PERK, p-eIF2a and eIF2a by Western blot in WT and CXCR3/ mice fed control or
MCD diet. (F) Apoptosis was determined by TUNEL staining in liver tissues from
WT and CXCR3/mice fed control or MCD diet. Ten random fields from five slides
per group were examined, and the TUNEL-positive brown nuclei within the
hepatocytes were counted. Data were expressed as the number of TUNEL-positive
cells/1000 cells. Data were expressed as mean ± SD, n = 5/group.Discussion
As CXCR3 is reported to be prominent in humans with insulin
resistance [10] and HCV related hepatitis [33], we first evaluated
the expression of CXCR3 in liver tissues of human NAFLD. CXCR3
was detected at a very low level in normal liver tissues, but
expression increased markedly in the NAFLD tissues. Consistent
with the enhanced expression of CXCR3 in human NAFLD tissues,
CXCR3 is markedly upregulated in experimental steatohepatitis
in both WT and db/db models. The CXCR3 induction was
coincided with increased serum ALT, hepatic triglyceride and166 Journal of Hepatology 2016 vol. 64 j 160–170
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JOURNAL OF HEPATOLOGYoxidative stress. To better define the effect of endogenous CXCR3
in the development of steatohepatitis, we examined its histolog-
ical consequences by using CXCR3/ mice; where CXCR3
deletion reduced the susceptibility to both MCD-induced and
HFHC-induced steatohepatitis compared with WT animals.
These data indicate that CXCR3 plays an important role in the
development of steatohepatitis.
The molecular mechanisms by which CXCR3 exerts its pro-
inflammation function in steatohepatitis were therefore evaluated.
CXCR3 and CXCR3-binding chemokines are suggested to be key
players in inflammatory processes; and are upregulated in
pro-inflammatory cytokine milieu [34]. Hepatic induction of
CXCR3 might be associated with the production of other pro-
inflammatory cytokines, thereby inducing liver inflammation in
steatohepatitis. Indeed, using a cytokine profiling analysis, we
identified that CXCR3 deletion significantly reduced pro-
inflammatory cytokines including TNF-a, IL-5 and MCP-1 (Fig. 3).
TNF-a is a key inflammatory cytokine in the development of
steatohepatitis and a major regulator of CXCR3 [35,36]. CXCR3 in
turn regulates the expression of TNF-a in inflammatory disease
conditions [37,38]. MCP-1 is a critical pro-inflammatory factor inJournal of Hepatology 201steatohepatitis as it can induce inflammation directly and stimu-
late lipogenesis to promote steatosis [39]. The interactions
between CXCR3 and MCP-1 have been well documented [40].
Therefore, the pro-inflammatory effect of CXCR3 in steatohepatitis
is at least in part related to the induction of its related
pro-inflammatory cytokines (TNF-a and MCP-1) (Fig. 7B). Since
NF-jB is an upstream regulator for TNF-a and MCP-1, which can
in turn activate NF-jB; NF-jB activation is involved in early hep-
atic inflammatory recruitment and liver injury in steatohepatitis
[39], we thus evaluated the effect of CXCR3 on NF-jB activation
in steatohepatitis. We revealed that CXCR3 induced NF-jB activa-
tion as evidenced by increased NF-jB DNA binding activity and
protein expression of NF-jB p50. In this regard, the pro-
inflammatory effect of CXCR3 in steatohepatitis is partly related
to the induction of these pro-inflammatory factor and cytokines
(Fig. 7B).
It is known that MCP-1 stimulates macrophage activation
[21]. CXCR3 is required for the recruitment and activation of
macrophages in animal models [9]. We demonstrated that CXCR3
deficiency reduced hepatic macrophage recruitment concomitant
with reduced expression MCP-1 and CCR2 (Fig. 3). The positive6 vol. 64 j 160–170 167
Research Article
association of CXCR3 and MCP-1 found in human NAFLD tissues
further suggested the effect of CXCR3 in steatohepatitis through
mediating macrophage infiltration. Our findings were supported
by other reports that macrophage infiltration is reduced when
CXCR3 is deleted genetically or blocked chemically [9,41]. More-
over, adoptive transfer of WT macrophages partially impaired the
ameliorated steatohepatitis in mice deficient with CXCR3. This
indicated that macrophage is one of the cell types that con-
tributes to the harmful effect of CXCR3 in steatohepatitis. All
these data suggest an important role of CXCR3 in inducing
macrophage recruitment and activation in steatohepatitis
development.
Excessive hepatic triglyceride accumulation in steatohepatitis
can be caused by enhanced synthesis of fatty acids and inhibited
fatty acid oxidation. We demonstrated that CXCR3 regulates hep-
atic fatty acids synthesis by stimulating fatty acid synthesis reg-
ulators including SREBP-1c, LXRs, FAS and SCD-1. SREBP-1c is a
transcription factor for triglyceride synthesis. It activates genes
required for fatty acid synthesis and storage of triglyceride such
as FAS and SCD-1 [42]. LXRs are members of metabolic nuclear
receptors, which play central roles in lipogenesis. It can also
bridge hepatic lipid metabolism and inflammation [43]. However,
factors related to fatty acid oxidation were not changed by
CXCR3. Thus, CXCR3 promotes hepatic steatosis mainly by induc-
ing key fatty acid synthesis genes (Fig. 7B).
Recent studies have reported that autophagy is involved in the
pathogenesis of steatohepatitis through hepatocyte lipid metabo-
lism, inflammation, insulin sensitivity and hepatocellular injury
[39,44,45]. One of the striking findings of this study is the identi-
fication of a key role of CXCR3 in the regulation of
autophagosome-lysosome system. We showed that p62 and
LC3-II protein levels were enhanced in MCD-fed WT mice with
severe steatohepatitis, whilst ablation of CXCR3 reduced p62
and LC3-II accumulation in accordance with ameliorated steato-
hepatitis (Fig. 6). Due to the fact that p62 and LC3-II are both
degraded in the autolysosome [46], the reduced lysosomal-
dependent turnover of these proteins indicates autophagic flux
impairment [47,48]. Moreover, the induction of LAMP1 and
LAMP2 in steatohepatitis by CXCR3 indicated lysosome storage
disorder in the process of steatohepatitis. CXCR3 is co-localized
with LAMP-1 and degraded in lysosomes of lymphocytes [49].
Our results suggested that CXCR3 inhibited autophagic flux in
steatohepatitis. We have reported that proteasome is activated
in a compensatory manner for protein degradation upon autop-
hagy inhibition [29]. Like p62, polyubiquitinated proteins are
sequestered into autophagosomes and degraded in autolyso-
somes [50]. Keeping with this, we found that removal of CXCR3
suppressed polyubiquitinated proteins and ER stress/UPR in
steatohepatitis (Fig. 6), which favors the restoration of autop-
hagy. Taken together, these findings indicated that CXCR3 is
involved in the inhibition of autophagy in steatohepatitis and
removal of CXCR3 improves steatohepatitis by restoring hepatic
autophagosome-lysosome system.
The induction of CXCR3 in experimental steatohepatitis and
the blunted development of dietary steatohepatitis in CXCR3/
mice compared to the WT mice led us to hypothesize that CXCR3
could be a potential therapeutic target in this disorder. If this is so,
selective CXCR3 antagonist should dampen or abrogate the devel-
opment of steatohepatitis. The AML-12 hepatocytes treated with
CXCR3 antagonist NIBR2130 in MCD culture medium clearly
reduced triglyceride and oxidative stress, together with decreased168 Journal of Hepatology 201expression of TNF-a and p62. In WT mice fed the MCD diet with
supplementary CXCR3 antagonist AMG487 or SCH546738, sub-
stantial reversed the established steatohepatitis supported by
improved liver histology, the significant reduction in intrahepatic
triglyceride and lipid peroxide levels, concomitant with decreased
macrophage infiltration and repaired autophagosome-lysosome
functions (Supplementary Fig. 5). Collectively, the observation
that CXCR3 antagonists impaired steatohepatitis in vitro or
effected regression of established steatohepatitis is both novel
and of potential clinical relevance.
This study demonstrates the essential role of CXCR3 in the
evolution of nutritional steatohepatitis. The mechanisms that
CXCR3 promotes steatohepatitis could be attributed to its pro-
inflammatory effects by upregulating critical inflammatory NF-
jB, cytokines, and macrophage infiltration; induction of fatty
acid accumulation through inducing lipogenesis and inhibition
of the autophagosome-lysosome system (Fig. 7B). These results
are congruent with reports that CXCR3 could aggravate obesity-
induced visceral adipose inflammation and systemic insulin
resistance in mice fed high-fat diet [40,51]. CXCR3 inhibition by
neutralizing anti-CXCR3 mAb ameliorates hepatocellular damage
induced by ischemia-reperfusion injury [52]. However, we found
genetic deletion of CXCR3 in CXCR3/ mice led to exacerbated
nutritional liver fibrosis, whilst hepatic infiltration of
interferon-c-positive T cells (Th1 cells) was reduced. Interferon-
c-positive T cells are considered as part of an antifibrotic immune
response [53]. Therefore, the enhanced liver fibrosis in CXCR3/
mice was at least in part associated with the decreased
interferon-c-positive T cell infiltration. In line with our findings,
other studies reported the antifibrotic effects of CXCR3 and its
ligand CXCL9 in carbon tetrachloride (CCL4)-induced liver fibrosis
in mice [5,32]. The beneficial effect of CXCR3 in liver fibrosis was
associated with intrahepatic interferon-c-positive T cells infiltra-
tion [5,32]. CXCR3/ mice displayed augmented liver damage in
CCL4-induced acute liver injury in mice [54]. A recent review arti-
cle has comprehensively summarized the effects of CXCR3 and its
ligands in liver fibrosis [22]. CXCR3 and its ligand CXCL9 exert
antifibrogenic function, while the ligand CXCL10 has profibro-
genic effect in the liver [22]. The different functions of CXCR3
ligands might explain the different roles of CXCR3 in different
stages of inflammation and fibrosis in the pathogenesis of steato-
hepatitis. Taken together, the function of CXCR3 in liver injury
appears to be context dependent, which might be due to differ-
ences in interferon responsiveness and the regulation of CXCR3
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